ADVERTISEMENT
April 19, 2012 at 10:38 AM EDT
Mixed Open As Existing Home Sales Fall

The markets opened mixed with the Dow losing 24 points to 13,008 while Nasdaq gained 10 points to 3041 as sales of existing homes fell in March.

On the upside

Human Genome Sciences (Nasdaq: HGSI) rejected GlaxoSmithKline's (NYSE: GSK) unsolicited $2.59 billion acquisition offer but will now explore strategic options including the possible sale of the company.


Gilead (Nasdaq: GILD) reported positive interim results from a Phase 2 clinical trial of its hepatitis C treatment GS-7977 plus pegylated interferon and ribavirin.


CVR Energy (NYSE: CVI) removed a poison which will now allow activist investor Carl Icahn to acquire the company.


On the downside


Shares of Achillion Pharmaceuticals (Nasdaq: ACHN) tumbled after Gilead reported upbeat interim results for its hepatitis C treatment. Achillion is developing its own hepatitis C drug


First Horizon National (NYSE: FHN) reported lower first quarter earnings that fell short of analyst expectations as bad loan provisions soared.

First quarter earnings climbed for EMC (NYSE: EMC) to top estimates but the data storage equipment company forecast full year earnings below analyst expectations.

In the broad market, declining issues outpaced advancers by a margin of 5 to 3 on the NYSE and by nearly 5 to 3 on Nasdaq. The Russell 2000 which tracks small cap stocks lost 3 points to 799.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here